STOKE THERAPEUTICS INC
STOKNASDAQ🏆 #1844 by market capEarnings Nov 2US Equity
$33.26▲ $0.30 (+0.91%)
Live1h▼ 0.1%
24h▲ 0.9%
7d▲ 4.1%
14d▲ 12.7%
30d▲ 13.0%
1y▲ 146.2%
🏦Market Cap
$2.07B
Small Cap
📈Revenue Growth (YoY)
-86.2%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
75.1x
Expensive
Otter Score
58
Weak
📊
Analyst Ratings
Price
$33.26
Total
16
Raised
2
Lowered
0
Avg PT
$47.33
H / L
$58 / $40
| Institution | Action | Rating | Date |
|---|---|---|---|
Wedbush | Reiterated | Outperform | 2026-08-04 |
Chardan Capital | Reiterated | Buy | 2026-08-04 |
Canaccord Genuity | Reiterated | Buy | 2026-08-04 |
Guggenheim | Reiterated | Buy | 2026-08-04 |
BTIG | Reiterated | Buy | 2026-05-11 |
Needham | Reiterated | Buy | 2026-03-17 |
HC Wainwright & Co. | Reiterated | Buy | 2025-12-15 |
JP Morgan | Reiterated | Neutral | 2025-11-03 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-12-10 |
TD Cowen | Upgraded | Hold → Buy | 2024-03-26 |
Credit Suisse | Reiterated | Outperform | 2023-08-08 |
B of A Securities | Upgraded | Underperform → Neutral | 2023-05-01 |
Jefferies | Reiterated | Buy | 2022-01-31 |
UBS | Reiterated | Neutral | 2021-05-18 |
H.C. Wainwright | Reiterated | Buy | 2019-10-25 |
Cowen & Co. | Reiterated | Outperform | 2019-07-15 |
One row per institution, most recent rating